Q4FY26 & FY26 results Revenue from operations at Rs 9,204 crore, up 16.6% YoY, ahead of stated guidance. EBITDA at Rs 1,789 crore up 21.8% YoY, EBITDA margins at 19.4%. Reported PAT at Rs 941 crore, up 33.1% YoY. Adj. PAT2 at Rs 1,008 crore, up by 40.9% YoY. Domestic business sales at Rs 4,027 crore, up 10.0% YoY. Growth in-line with market, led by cardiac, CNS and oncology. Consolidated domestic operations with subsidiary minority stake buyout, strengthened leadership teams across divisions and expanded portfolio via key MNC partnerships. International business sales at Rs 5,177 crore, up 22.2% YoY. Strong momentum from base business growth and new launches from in-house portfolio.

#FundamentalViews#WatchOutFor#MacroViews#EquityResearch#TrendingSectors

1,144 likes·91 comments